Navigation Links
Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives
Date:12/3/2008

and advancing our preclinical pipeline, while maintaining a strong balance sheet. We have established important commercial agreements in the non-therapeutic aspects of our technology with Dow Agrosciences in plant agriculture and Sigma-Aldrich Corporation in research reagents. We also have agreements with Genentech and Pfizer in cell-line engineering. We plan to establish strategic partnerships around our therapeutic programs at points of value inflection and expect 2009 to be another year of significant accomplishments for Sangamo."

Mr. Lanphier continued, "We are pursuing a broad development program for our lead ZFP Therapeutic(TM), SB-509, an activator of vascular endothelial growth factor (VEGF) with three Phase 2 clinical trials ongoing for the treatment of diabetic neuropathy (DN) and one to evaluate its use in the treatment of amyotrophic lateral sclerosis (ALS). We have also advanced our preclinical pipeline and expect to file Investigational New Drug (IND) application for the first of our ZFN-based therapeutic programs for HIV/AIDS before the end of 2008.

"We are very pleased by the progress of our non-therapeutic collaborations this year. Our partner Sigma-Aldrich successfully launched the CompoZr brand of ZFN-based gene editing tools and we look forward to the increased interest and further validation of the technology that this broadening of the user-base will bring. We also transitioned ahead of schedule into the commercial phase of our collaboration with Dow AgroSciences (DAS) to apply our ZFP technology for plant agriculture and expect DAS to begin to sublicense the technology in that industry. The success of these activities is key to further enhancing the market-leading presence for our technology. We believe that our progress in advancing our technology platform, which is unique in its generation of novel, highly differentiated therapies and products, will create interest among potential pharmace
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
2. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
3. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
4. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
7. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
8. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
11. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... --   Masimo (NASDAQ: MASI ... Acoustic Monitoring™, and Masimo SET ® Measure-Through Motion ... Medical Devices, Inc. dismissed all outstanding claims against Masimo ... and Cercacor.   Masimo did not incur any liability to ...
... QBC Diagnostics, a global manufacturer of hematology ... the company has been awarded a U.S. General ... Equipment and Services. GSA,s Scientific Equipment ... with scientific instruments for a wide variety of ...
Cached Medicine Technology:Essential Medical Dismisses Patent Case against Masimo and Cercacor 2Essential Medical Dismisses Patent Case against Masimo and Cercacor 3Essential Medical Dismisses Patent Case against Masimo and Cercacor 4QBC Diagnostics Awarded GSA Contract 2
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
(Date:4/17/2014)... 2014 EcoHealth Alliance, a nonprofit organization that focuses ... comprehensive review today examining the current state of knowledge ... calls for improved global surveillance strategies to combat the ... of Ebola in West Africa that has claimed the ... and Liberia. According to the World Health Organization ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... national provider of tele-health solutions, has received full accreditation from URAC ... URAC assures that SironaHealth has met all relevant standards and performs ... is timely, confidential, and includes medically appropriate care and treatment advice. ... ...
... complete medical travel packages for North American patients seeking ... ... Long Beach, Calif. (PRWEB) April 8, 2009 -- With U.S. ... trillion this year, health insurers, self-insured employers, groups and individuals are ...
... Multiple, anatomically distinct lung cancer tumors may frequently arise ... analysis of patient tumor samples published in the April ... National Cancer Institute. , Some lung cancer patients ... diagnosis. Although such multiple tumors usually share a common ...
... that the growth factor known as TGF-β is essential to ... blocking it can cause retinal dysfunction. These findings, published in ... have an important impact on the prevention and treatment of ... results are significant because they add to our understanding of ...
... testing after ,very promising, early results, , , TUESDAY, April ... radically different way of attacking prostate cancer has done ... larger-scale testing, researchers report. , One standard treatment for ... male hormones such as testosterone that help drive tumor ...
... women, not men, researchers report , , TUESDAY, April 7 ... the list of cardiac problems linked to overweight and ... however we measure it, is associated with the risk ... fellow at the Cardiovascular Epidemiology Research Unit of Beth ...
Cached Medicine News:Health News:SironaHealth Receives URAC Accreditation as a Health Call Center 2Health News:SironaHealth Receives URAC Accreditation as a Health Call Center 3Health News:Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers 2Health News:Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers 3Health News:Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers 4Health News:Multifocal lung cancers appear to originate from single cancer clone 2Health News:Growth factor TGF-B helps maintain health of retinal blood vessels 2Health News:New Prostate Cancer Drug May Hold Promise 2Health News:New Prostate Cancer Drug May Hold Promise 3Health News:Obesity Linked to Heart Failure Risk 2
... Sorvall DiscoveryTMM150 SE Micro-ultra centrifuge continues to ... sample processing, now with 1,048,000 x g ... rotor. DiscoveryTMM150SE processes sample sizes from ... small floor footprint, brushless direct drive, very ...
... and environmental safety are the ... K Ultracentrifuge from Beckman Coulter. ... centrifugation technology, the LE-80 K ... provide advanced capability for your ...
... Optima L-XP ultracentrifuge is designed to ... discovery process if research involves proteomics, ... sophisticated on-board computer, enhanced firmware, powerful ... touch screen, Optima L-XP delivers superior ...
... chemistry system brings versatility in a ... laboratory. A model of innovation and ... system features state-of-the-art Dimension testing technology, ... in a flexible. affordable, easy-to-use system ...
Medicine Products: